{"schema_version":"secwatch.filing_event.v1","accession":"0001932393-23-000086","form_type":"8-K","ticker":"GEHC","cik":"0001932393","company_name":"GE HealthCare Technologies Inc.","filed_at":"2023-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.595418+00:00","generated_at":"2026-06-16T17:00:38.800560+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"GE HealthCare Q1 revenue up 12% organic; adjusted EPS $0.85; reaffirms FY guidance","bullets":["Revenue $4.7B, +8% reported, +12% organic; strong across all segments: Imaging, Ultrasound, PCS, PDx.","Net income attributable $372M; adjusted EBIT $664M, margin 14.1% (+30bps); adjusted EPS $0.85 vs $0.96.","Cash from ops $468M, free cash flow $325M; FY guidance: organic revenue growth 5-7%, adj. EPS $3.60-$3.75.","Board declares dividend $0.03/share; FY adjusted EBIT margin guided 15.0-15.5%.","Segment margins: Imaging 7.7% (down), Ultrasound 24.1% (up), PCS 14.0% (up), PDx 27.8% (down)."],"urls":{"canonical":"https://secwatch.observer/filing/0001932393-23-000086","json":"https://secwatch.observer/filing/0001932393-23-000086.json","markdown":"https://secwatch.observer/filing/0001932393-23-000086.md","text":"https://secwatch.observer/filing/0001932393-23-000086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1932393/000193239323000086/0001932393-23-000086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1932393/000193239323000086/gehc-20230425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T17:00:38.800560+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ecb2e18f8fa93363cd52fc10a19d88e00779fc71","claim":"GE HealthCare Technologies Inc. reported First Quarter 2023 results: revenue $4.7 billion, net income $372 million, EPS $0.41. Guidance reaffirmed.","evidence_excerpt":"• Revenues of $4.7 billion increased 8% reported and 12% on an Organic basis* year-over-year. Foreign exchange negatively impacted growth by 4%. Total company book-to-bill, defined as Total orders divided by Total revenues, was 1.01 times for the quarter, given strong revenue growth across all segments, led by Pharmaceutical Diagnostics (PDx) recurring sales. • Net income attributable to GE HealthCare was $372 million versus $389 million for the prior year, and Adjusted EBIT* was $664 million versus $599 million. • Net income margin was 7.9% versus 9.0% for the prior year, down 110 basis points (bp s) primarily impacted by interest expense. Adjusted EBIT margin* was 14.1% versus 13.8%, up 30 bps driven by volume, partially offset by mix. Inflation and planned investments were mostly offset by price and productivity actions. Adjusted EBIT margin* for the first quarter of 2023 grew 150 bps versus our estimated 1Q’22 Standalone Adjusted EBIT margin*. • Earnings per share (EPS) f rom conti","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000193239323000086/0001932393-23-000086-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"First Quarter 2023"},{"label":"Revenue","value":"$4.7 billion"},{"label":"Net income","value":"$372 million"},{"label":"EPS","value":"$0.41"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}